Company Legal Name
Latest Valuation
Founded Year
Headquarter
Tahoe Therapeutics is a biotechnology company that leverages artificial intelligence models combined with in vivo data to accelerate drug discovery and development. Founded in 2022 and headquartered in South San Francisco, the company differentiates itself by integrating AI-driven computational approaches with real-world biological data to identify therapeutic candidates that can benefit broader patient populations. This hybrid methodology aims to address traditional drug discovery limitations by improving target identification and reducing development timelines. As an early-stage company, Tahoe Therapeutics is focused on building its AI platform capabilities and advancing its pipeline of drug candidates across multiple therapeutic areas.
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
